Skip to main content

Another Study Finds CRISPR Gene Therapy Fights Sickle Cell

Medically reviewed by Carmen Pope, BPharm. Last updated on June 18, 2024.

By Ernie Mundell HealthDay Reporter

TUESDAY, June 18, 2024 -- There's more good news in the battle against sickle cell disease, with another trial finding CRISPR gene-editing therapy delivering impressive results for patients.

“It’s encouraging that this gene-editing treatment continues to show promising efficacy for sickle cell patients,” said study lead investigator Dr. Rabi Hanna. He's chair of the division of pediatric hematology oncology and blood and marrow transplantation at Cleveland Clinic Children’s.

Sickle cell anemia is a painful, inherited genetic disorder which creates misshapen sickle-shaped red blood cells. Over 100,000 Americans are thought to have sickle cell disease, which can shorten life spans and is much more common among Black Americans.

Recent advances in what's known as CRISPR gene-editing technology helps correct the disorder by tweaking the underlying gene abnormality behind it.

The Cleveland Clinic CRISPR approach is called renizgamglogene autogedtemcel (shortened to "reni-cel"). It's am experimental one-time treatment that uses the patient's own stem cells to correct the genetic abnormality.

Two of the 18 patients in the new trial were treated at the Cleveland Clinic.

In the procedure, patients' stem cells are harvested and then sent for gene editing in the lab. Patients also underwent chemotherapy to make room for the new stem cells to be infused into their bone marrow.

"Following treatment, all patients successfully regained their white blood cells and platelets," according to a clinic news release. "Importantly, all patients have remained free of painful events since treatment, and those followed for five months or greater have seen their anemia resolve."

The treatment also appeared to have no serious side effects, Hanna's group reported.

"These latest results offer hope that this new experimental treatment will continue to show progress and get us closer to a functional cure for this devastating disease," he said.

The findings were presented Thursday at the European Hematology Association 2024 Hybrid Congress (EHA) in Madrid. Such findings should be considered preliminary until published in a peer-reviewed journal.

The trial was funded by gene-editing company Editas Medicine.

Sources

  • Cleveland Clinic, news release, June 14, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted June 2024

Read this next

Chemo Drug, Hydroxyurea, Effective For Kids With Sickle Cell Disease

MONDAY, April 21, 2025 -- An oral chemotherapy drug can safely and effectively manage sickle cell disease in children, a new study says. Children taking hydroxyurea had fewer ER...

Menstrual Cycle Could Be Contributing To Sickle Cell Pain Events

MONDAY, April 14, 2025 -- Women with sickle cell disease often have pain crises around the time of their period, and researchers now think they know why. Inflammation increases...

First Patient Cured of Sickle Cell Anemia

MONDAY, March 17, 2025 -- For 21 years, Sebastien Beauzile lived with the chronic pain of sickle cell anemia.  Now, thanks to a groundbreaking genetic treatment, he is the...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.